Regulation of human erythropoiesis

Information

  • Research Project
  • 10228572
  • ApplicationId
    10228572
  • Core Project Number
    P01DK032094
  • Full Project Number
    5P01DK032094-33
  • Serial Number
    032094
  • FOA Number
    PAR-16-127
  • Sub Project Id
    5516
  • Project Start Date
    1/30/1997 - 28 years ago
  • Project End Date
    7/31/2022 - 2 years ago
  • Program Officer Name
  • Budget Start Date
    8/1/2021 - 3 years ago
  • Budget End Date
    7/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    33
  • Suffix
  • Award Notice Date
    8/16/2021 - 3 years ago

Regulation of human erythropoiesis

Project Summary Our purpose in this project is to illuminate the complexities of the mechanisms regulating erythropoiesis in man. We believe that there is a pressing need for such a study since erythroid cell development differs in critical respects from that of most other cells, on which current knowledge largely rests. Erythropoiesis is a distinctive process in that each mitosis generates daughter cells that are morphologically and functionally distinct from their parent cell. This has a direct clinical bearing since disordered erythropoiesis, a feature of several anemias including Diamond-Blackfan Anemia (DBA) and myelodysplastic syndromes (MDS) result from stage specific defects in erythroid differentiation. In the proposed studies, we will focus on two of the most important aspects of erythroid differentiation, namely the mechanistic bases regulating erythroid progenitor generation and terminal erythroid differentiation including enucleation. In order to accomplish these objectives, we propose two specific aims. In the first aim we hypothesize that erythroid progenitors, BFU-E and CFU-E, are heterogeneous cell populations characterized by changes in specific gene expression patterns. Resolving this question will be an essential step towards understanding the molecular basis for disordered erythropoiesis in DBA as erythroid developmental defects in DBA arise at the progenitor stage. Our second aim will explore the multifarious mechanisms regulating the expression of anti-apoptotic genes in polychromatic and orthochromatic erythroblasts and the subsequent induction of mitosis/cytokinesis genes allowing enucleation of orthochromatic erythroblasts. We hypothesize that deregulation of gene expression at these developmental stages are responsible for apoptosis of terminally differentiating cells in MDS. We anticipate that successful accomplishment of the proposed studies will provide novel insights into normal erythroid cell development as well as into diseases associated with disordered erythropoiesis. The recognition in recent years of an increasing number of conditions linked to anomalies of erythropoiesis, lend new urgency to pursue the proposed studies in view of the paucity of effective treatments. We hope and expect that the research direction we propose may lay the groundwork for developing novel therapeutic strategies.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    P01
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
    182963
  • Indirect Cost Amount
    108222
  • Total Cost
  • Sub Project Total Cost
    291185
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIDDK:291185\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZDK1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NEW YORK BLOOD CENTER
  • Organization Department
  • Organization DUNS
    073271827
  • Organization City
    NEW YORK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    100656275
  • Organization District
    UNITED STATES